NIH Funding Opportunities

Notice of NIAAA's participation in PAR-19-133, Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15-Clinical Trial Not Allowed)
Notice NOT-AA-19-001 from the NIH Guide for Grants and Contracts
Tue, 22 Jan 2019 12:10:04 EST

Notice of NIAAA's participation in PAR-19-134, Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed)
Notice NOT-AA-19-002 from the NIH Guide for Grants and Contracts
Tue, 22 Jan 2019 10:32:37 EST

Notice of NIAAA's participation in PAR-19-135, Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Required)
Notice NOT-AA-19-003 from the NIH Guide for Grants and Contracts
Tue, 22 Jan 2019 11:59:19 EST

Notice of NIAAA's participation in NOT-OD-19-040 "Notice of Interest in Long-term Maintenance of Behavior Change Research"
Notice NOT-AA-19-004 from the NIH Guide for Grants and Contracts
Tue, 22 Jan 2019 11:46:52 EST

Notice of Termination of PAR-19-164 "Summer Research Education Experience Program (R25 Clinical Trial Not Allowed)"
Notice NOT-AA-19-005 from the NIH Guide for Grants and Contracts
Wed, 23 Jan 2019 10:54:15 EST

Notice of NIA's Withdrawal from Participation in RFA-DK-18-030, "HEAL Initiative: Integrated Approach to Pain and Opioid Use in Hemodialysis Patients: The Hemodialysis Opioid Prescription Effort (HOPE) Consortium - Clinical Centers"
Notice NOT-AG-19-001 from the NIH Guide for Grants and Contracts
Tue, 22 Jan 2019 12:59:48 EST

Notice of NIA's Withdrawal from Participation in RFA-DK-18-031, "HEAL Initiative: Integrated Approach to Pain and Opioid Use in Hemodialysis Patients: The Hemodialysis Opioid Prescription Effort (HOPE) Consortium - Scientific and Data Research Center"
Notice NOT-AG-19-002 from the NIH Guide for Grants and Contracts
Tue, 22 Jan 2019 12:35:09 EST

Notice of Change to Application Types for PAR-18-696, "Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Natural Products (Collaborative UG3/UH3 Clinical Trial Required)"
Notice NOT-AT-19-016 from the NIH Guide for Grants and Contracts
Tue, 22 Jan 2019 09:04:25 EST

Notice of Pre-Application Webinar for the NIH Consortium for Advancing Research on Botanical and Other Natural Products (CARBON) Program: RFA-AT-19-002, RFA-AT-19-003 and RFA-OD-19-001
Notice NOT-AT-19-020 from the NIH Guide for Grants and Contracts
Wed, 23 Jan 2019 01:42:37 EST

Notice of Clarification: Funds Available for RFA-DE-19-008 Enabling Technologies to Accelerate Development of Oral Biodevices (R21 Clinical Trial Not Allowed)
Notice NOT-DE-18-028 from the NIH Guide for Grants and Contracts
Tue, 22 Jan 2019 11:05:21 EST

Notice of Clarification: Funds Available for RFA-DE-19-009 Enabling Technologies to Accelerate Development of Oral Biodevices (R01 Clinical Trial Not Allowed)
Notice NOT-DE-18-029 from the NIH Guide for Grants and Contracts
Tue, 22 Jan 2019 11:19:44 EST

Notice of Modifications to Instructions for Letters of Support in PAR-19-102 "Graduate Research Training Initiative for Student Enhancement (RISE) (T32)"
Notice NOT-GM-19-017 from the NIH Guide for Grants and Contracts
Tue, 22 Jan 2019 09:36:17 EST

Notice of Intent to Publish a Funding Opportunity Announcement for Medical Rehabilitation Research Resource (P2C Clinical Trial Optional)
Notice NOT-HD-18-026 from the NIH Guide for Grants and Contracts
Tue, 22 Jan 2019 11:15:24 EST

Notice of Change Application Due Date(s) for RFA-HD-19-024 "Womens HIV Epidemiology Cohort Studies (R01 - Clinical Trial Not Allowed)"
Notice NOT-HD-19-002 from the NIH Guide for Grants and Contracts
Tue, 22 Jan 2019 11:39:51 EST

Notice of Change: Emphasizing Opportunity for Developing Comprehensive Human Genome Sequencing Methodologies in Response to NHGRI Novel Nucleic Acid Sequencing Technology Development FOAs
Notice NOT-HG-19-011 from the NIH Guide for Grants and Contracts
Tue, 22 Jan 2019 10:23:10 EST

Notice of NHLBI Participation in PA-19-165 "Administrative Supplement for Research on Sex/Gender Influences (Admin Supp Clinical Trial Optional)"
Notice NOT-HL-19-675 from the NIH Guide for Grants and Contracts
Wed, 23 Jan 2019 01:00:57 EST

Notice of Data Sharing Policy for the BRAIN Initiative
Notice NOT-MH-19-010 from the NIH Guide for Grants and Contracts
Tue, 22 Jan 2019 01:26:31 EST

Additional Information Regarding RFA-OD-18-001 "Tobacco Regulatory Science Small Grant Program for New Investigators (R03 Clinical Trial Optional)" and RFA-OD-18-003 "Tobacco Regulatory Science (R21 Clinical Trial Optional)"
Notice NOT-OD-19-047 from the NIH Guide for Grants and Contracts
Wed, 23 Jan 2019 10:03:41 EST

Notice of Clarification of Eligibility for PAR-19-114 "Non-human Primates Facilities to Support HIV/AIDS-related Research (C06) (Clinical Trial Not Allowed)"
Notice NOT-OD-19-061 from the NIH Guide for Grants and Contracts
Tue, 22 Jan 2019 11:29:48 EST

Notice of Intent to Publish the Reissuance of RFA-OD-18-002 "Tobacco Regulatory Science (R01 Clinical Trial Optional)"
Notice NOT-OD-19-062 from the NIH Guide for Grants and Contracts
Wed, 23 Jan 2019 10:03:40 EST

Notice of Participation of the Office of Research on Womens Health (ORWH) in RFA-DA-19-029, HEAL Initiative: HEALthy Brain and Child Development Study (HEALthy BCD) (Collaborative R34 Clinical Trial Not Allowed) and RFA-DA-19-036, HEAL Initiative: HEA
Notice NOT-OD-19-063 from the NIH Guide for Grants and Contracts
Tue, 22 Jan 2019 12:25:25 EST

The National Institutes of Health (NIH) Sexual and Gender Minority Research Office (SGMRO) Announces Pacific Regional Workshop on Sexual and Gender Minority (SGM)-Related Research
Notice NOT-OD-19-064 from the NIH Guide for Grants and Contracts
Tue, 22 Jan 2019 09:27:51 EST

Natural Products NMR Open Data Exchange (NP-NODE) (U24 Clinical Trial Not Allowed)
Funding Opportunity RFA-AT-19-002 from the NIH Guide for Grants and Contracts. The National Center for Complementary and Integrative Health (NCCIH) with the Office of Dietary Supplements (ODS) solicit applications for the development of an NMR Open Data Exchange (NP-NODE) and associated efforts to accelerate coordination and data sharing among natural products researchers more broadly. The NP-NODE will create the resources necessary to facilitate the capacity to upload, download, store, search and analyze raw NMR data. This resource will comply with the principle that scientific data should be Findable, Accessible, Interoperable, and Reusable (FAIR). Ultimately, this resource will provide natural products researchers the power to mine NMR data in ways that are currently not possible. In parallel, the NP-NODE will develop an outreach plan to obtain input from diverse communities of researchers to develop consensus on the format and most critical features of the data repository. More broadly, the FOA supports and requires the coordination across the natural products research community to facilitate development of standards to accelerate sharing of data relevant to natural product chemistry and biology. Finally, the NP-NODE will serve an advisory function to assist NCCIH and ODS grantees in complying with the NCCIH Product Integrity Policy.
Tue, 22 Jan 2019 12:52:10 EST

Center for Natural Product Technology, Methodology, and Productivity Optimization (NP-TEMPO) (U41 Clinical Trial Not Allowed)
Funding Opportunity RFA-AT-19-003 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to establish a National Center for Natural Product Technology Methodology and Performance Optimization (NP-TEMPO). This initiative is to improve upon and strengthen technologies and methods used in natural products research. The NP-TEMPO, supported through the U41 cooperative agreement funding mechanism, is expected to overcome existing research limitations by developing and/or adapting cutting edge, innovative approaches and technologies that will have significant impact on the chemical and biological annotation of natural products. This FOA is being released in conjunction with the National Center for Complementary and Integrative Health (NCCIH) NMR Open Access Data Exchange and the Office of Dietary Supplements (ODS) Botanical Dietary Supplement Research Centers Program. Collectively, the awards under these FOA constitute the NCCIH/ODS Centers Advancing Research on Botanical and Other Natural Products (CARBON) Program. Applicants applying under this NP-TEMPO FOA are encouraged to collaborate with the NODE, the Botanical Dietary Supplement Research Centers, and other NCCIH, ODS, and NIH supported grantees through NP-TEMPO Technology Demonstration Projects (TDPs).
Tue, 22 Jan 2019 12:52:13 EST

Establishing a Cohort to Clarify Risk and Protective Factors for Neurocognitive Complications of Pediatric Type 1 Diabetes (T1D) - Planning Cooperative Agreements (U34 Clinical Trial Not Allowed)
Funding Opportunity RFA-DK-18-007 from the NIH Guide for Grants and Contracts. This FOA invites applications for planning cooperative agreements (U34) for a national, multisite, observational cohort study to prospectively examine the risk and protective factors for neurocognitive complications of pediatric type 1 diabetes (T1D; onset approximately ages 5-10 years) and a comparison sample. The U34 is designed to: 1) Permit early peer review of the rationale for the proposed cohort study; 2) Permit assessment of the study design; and 3) Provide support for the development of essential elements required for the design and conduct of the cohort study and the management and analysis of the study data. Consultation with NIDDK scientific staff is strongly encouraged prior to the submission of the U34 application.
Wed, 23 Jan 2019 11:28:38 EST

Mass Spectrometric Assays for the Reliable and Reproducible Detection of Proteins/Peptides of Importance in Obesity Research (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-DK-19-001 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing the development of targeted mass spectrometric assays (e.g., Multiple Reaction Monitoring) for proteins and peptides of primary interest to the obesity research community (e.g., Adiponectin, Leptin, Resistin, Neuropeptide Y, Alpha-melanocyte-stimulating hormone, Peptide YY, Glucagon-like peptide 1, Ghrelin, Adrenocorticotropin, Corticotropin-releasing hormone, Gastrin, Cholecystokinin, Secretin, Vasoactive intestinal peptide, gastric-inhibitory peptide, gastrin-releasing peptide, motilin, pancreatic polypeptide,RBP4,myostatin, FGF21). The proposed assays should be highly reproducible, easily transferable to other laboratories, easy to multiplex, and validated in human plasma or serum.
Wed, 23 Jan 2019 11:44:48 EST

Botanical Dietary Supplements Research Centers (U19 Clinical Trial Optional)
Funding Opportunity RFA-OD-19-001 from the NIH Guide for Grants and Contracts. Through this Funding Opportunity Announcement (FOA), the participating components invite applications to support Botanical Dietary Supplements Research Centers (BDSRC), which will constitute one component of the Consortium for Advancing Research on Botanicals and Other Natural Products (CARBON.2). The purpose of the BDSRC is to support collaborative, trans-disciplinary research that will contribute significantly to the optimal design of future clinical trials of the effects on human resilience of orally consumed, complex botanical products. The BDSRC are expected to focus on developing the most critical data to inform the optimal design of such future trials. Information acquired through achievement of the BDSRC specific aims is expected to allow for the design of optimally informative clinical trials, providing evidence for design decisions including, but not limited to, decisions about the appropriateness of the trial design (or of doing any trial with the product), as well as those regarding product formulations, doses, timing, eligibility criteria, participant characteristics to be collected, markers of proximal biological effect, outcome measures, etc. Products appropriate for applications responsive to the planned FOA will be limited to those for which there is rigorous, but not definitive, evidence supporting a clinically or public health significant, biologically and mechanistically plausible, and reproducible effect on, or relevant to, human biological or psychological resilience. Applications in which a purified phytochemical is the main focus will be considered unresponsive to the FOA. Applicants applying under this BDSRC FOA are encouraged to collaborate, as appropriate, with other CARBON.2 components, including the NMR Open Data Exchange (NODE) and the Center for Natural Product Technology, Methodology and Productivity Optimization (NP-TEMPO), as well as with other NCCIH, ODS, and NIH supported grantees.
Tue, 22 Jan 2019 12:52:11 EST

Implementation of shared decision making for HLBS diseases and conditions (R01 Clinical Trial Optional)
Funding Opportunity PA-19-166 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to support research that uses evidence-based practical approaches to increase uptake of shared decision making (SDM) into routine clinical practice. To determine how to implement SDM in pragmatic settings, several areas will need to be addressed such as how to best engage patients/surrogates in the decision process; how to identify when and for whom decisions are needed; how to educate/train physicians and non-physician providers about both the importance of SDM and how to do it; how to use EHRs and other technologies to identify patients who need to make decisions, and how to capture SDM encounters and outputs; and how to incorporate SDM encounters into the clinical workflow without undue burden on staff or patients. Proposed projects will be required to consider using existing SDM evidence, knowledge, and approaches, tools, and curricula to the extent feasible. This initiative will require multi-disciplinary teams to conduct pragmatic research in clinical practice settings and other relevant settings such as community or public health clinics. Research teams should address patient, provider, contextual, and systems level factors including, but not limited to, healthcare provider education; patients with low health literacy skills; electronic healthcare record requirements to support SDM execution; clinical workflow issues that impede implementation of SDM; evaluation of SDM; and need for sustainable health care teams and models to implement SDM in real-world settings.
Tue, 22 Jan 2019 11:15:51 EST

Development and Validation of Advanced Mammalian Models for Alzheimers Disease-Related Dementias (ADRD) (R61/R33 Clinical Trial Not Allowed)
Funding Opportunity PAR-19-167 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages research to develop, characterize and validate innovative mammalian models that recapitulate molecular, cellular, neuropathological, behavioral and cognitive hallmarks of the Alzheimers Disease-Related Dementias (ADRD), including Lewy body dementia (LBD), vascular contributions to cognitive impairment and dementia (VCID), frontotemporal degeneration (FTD) and mixed etiology dementias (MED). Models will be expected to exhibit a broad range of features characteristic of the dementia disorder being modeled, including a mid- to late-life onset consistent with the human disorder, multiple age-dependent neuropathological processes and the associated behavioral, cognitive and/or physiological abnormalities. For each proposed mammalian model, a relevant suite of phenotypes that inform human ADRD disease progression and mechanisms should be characterized across the full life span or, for longer-living mammalian models, throughout the disease-relevant stages of adulthood. The goal of this FOA is to establish multi-dimensional mammalian models for ADRD to serve as tools to interrogate molecular disease mechanisms and identify therapeutic targets.
Wed, 23 Jan 2019 01:35:41 EST